Sep 29, 2014

CONTACT Oncoceutics Receives ONC201 Research Grant From Musella Foundation For Brain Tumor Research & Information Hummelstown, PA (June 18, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that the Musella Foundation For Brain Tumor Research & Information, Inc, has awarded Oncoceutics a research grant to study ONC201 in glioblastoma multiforme (GBM), the most aggressive form of human brain cancer.The funded research project entitled “Target Identification of ONC201, a First-in-Class Drug to Treat Glioblastoma” aims to enhance the molecular understanding of how ONC201 kills brain tumor cells. Preclinical studies by several leading investigators indicate that ONC201 is highly effective at treating GBM in both cell culture and in animal models, including refractory primary patient samples and cancer stem cells. The Musella Foundation grant will fund laboratory studies assessing GBM cells that trigger strong antitumor effects in response to ONC201. “I am elated to receive support for this important project from the Musella Foundation, which underscores the high therapeutic potential that ONC201 represents for patients with GBM,” said Joshua Allen, Director of Development, Co-Inventor of ONC201, and Principal Investigator of the Musella Foundation grant. “These funds will yield key information about how this unique molecule is effective in GBM, which can help to both guide how patients with this devastating disease are treated with this new therapy and how future drugs could be created to be even more effective and safe.” “The Executive Board and Medical Advisors at the Musella Foundation were extremely impressed with this project for ONC201,” said Al Musella, DPM, President of the Musella Foundation. We are optimistic that ONC201 could be a major breakthrough in the treatment of brain tumors.” On February 28, the U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the Phase I/II trial of ONC201, and the company expects to begin clinical trials during the third quarter of 2014. Patients with advanced GBM will be assessed as part of these trials as a result of the strong pre-clinical data suggesting that ONC201 is likely to be effective at treating GBM. About The Musella Foundation The Musella Foundation For Brain Tumor Research & Information, Inc, is a 501(c)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. Funds to support research grants were raised from the National Walk To End Brain Tumors (www.WalkToEndBrainTumors.org). The Musella Foundation has been involved in supporting research, regulatory approval, and reimbursement strategies for several of the cornerstones of GBM treatment, including Temodar, Avastin, Gliadel, and NovoCure TTF. About Oncoceutics Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. On February 28, the U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the Phase I/II trial of ONC201, and the company expects to begin clinical trials during the third quarter of 2014. Contact: Lee Schalop, Chief Business Officer, lee.schalop@oncoceutics.com. Safe Harbor Forward-Looking Statements To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Photostream